The findings demonstrated that the use of new antidiabetic drugs, including sodium-glucose transport-2 inhibitor (SGLT-2i), glucagon-like peptide-1 receptor agonist, and dipeptidyl peptidase-4 inhibitor (DPP-4i), was associated with a decreased incidence of hypoglycemia when compared to pre-Ramadan and sulfonylurea therapies. The gene discussed is GLP1R; the disease is Hypoglycemia.